PDF) Cross-species higher sensitivities of FcγRIIIA/FcγRIV to afucosylated IgG for enhanced ADCC

Por um escritor misterioso

Last updated 09 julho 2024

The Current Landscape of Antibody-based Therapies in Solid Malignancies

Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

Enhancing FcγR-mediated antibody effector function during persistent viral infection

Site-Specific Glycosylation Mapping of Fc Gamma Receptor IIIb from Neutrophils of Individual Healthy Donors

Frontiers Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies

Cancers, Free Full-Text

Glycosylation of Antigen-Specific Antibodies: Perspectives on Immunoglobulin G Glycosylation in Vaccination and Immunotherapy

Enhancing FcγR-mediated antibody effector function during persistent viral infection

JCI - Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models

Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose

Fc‐Receptors as Regulators of Immunity - ScienceDirect

Cancers, Free Full-Text

Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) in Cancer

Loop Grafting between Similar Local Environments for Fc-Silent Antibodies

PDF) Beyond antibody fucosylation: α-(1,6)-fucosyltransferase (Fut8) as a potential new therapeutic target for cancer immunotherapy

Recomendado para você